Monday, December 8, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Upgrades Oracle to Outperform with 159 Price Target

Elaine Mendonca by Elaine Mendonca
March 12, 2024
in Breaking News
0
Technology Robotics Trading online
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

Analyst Mark Moerdler from Bernstein is bullish on Oracle (NYSE:ORCL) as of March 12, 2024. He has upgraded the stock to Outperform and increased the price target to $159, citing a positive outlook for the company. Moerdler specifically praises Oracle’s advancements in cloud computing and generative AI, which have positioned them well in the market.

A consensus of 34 analysts also supports an Outperform rating for Oracle, with an average target price of $124.7 USD. Some analysts have noted similarities between Oracle and Microsoft in their cloud transition strategies and operating margins.

Oracle’s focus on customer choice and hybrid environments is seen as a strategic move to meet diverse needs and ensure customer success. This customer-centric approach has been a key factor in Oracle’s success in the market.

Oracle Corporation (ORCL) Stock Shows Strong Performance on March 12, 2024

On March 12, 2024, Oracle Corporation (ORCL) showed strong performance in the stock market, with the stock trading near the top of its 52-week range and above its 200-day simple moving average. This indicates positive price momentum for the company.

The price of ORCL shares increased by $1.71 since the market last closed, representing a 1.52% rise from the previous day’s closing price of $114.13. This uptick in price suggests that investors are feeling optimistic about the company’s prospects.

In pre-market trading, the stock continued to show impressive growth, with a further increase of $14.57.

Overall, ORCL’s stock performance on March 12, 2024, reflects strong investor confidence in the company. Investors will be closely watching to see if this momentum continues in the days ahead.

Oracle Corporation (ORCL) Reports Strong Financial Performance with 17.7% Revenue Increase

On March 12, 2024, Oracle Corporation (ORCL) saw a strong performance in terms of its financials. According to data from CNN Money, the tech giant reported total revenue of $49.95 billion for the past year, representing a 17.7% increase compared to the previous year. In the second quarter of the fiscal year, Oracle reported total revenue of $12.94 billion, showing a 3.92% increase from the previous quarter.

Similarly, Oracle’s net income also showed positive growth trends. The company reported a net income of $8.50 billion for the past year, marking a 26.59% increase compared to the previous year. In the second quarter, Oracle reported a net income of $2.50 billion, showing a 3.43% increase from the previous quarter.

Earnings per share (EPS) for Oracle also saw significant growth. The company reported an EPS of $3.07 for the past year, reflecting a 27.5% increase compared to the previous year. In the second quarter, Oracle reported an EPS of $0.89, showing a 3.65% increase from the previous quarter.

Tags: ORCL
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Healthcare-and-Tech

RBC Capital Analyst Initiates Coverage on DexCom with Positive Outlook and Unveils Groundbreaking OvertheCounter CGM

Bioventus Surges in Stock Prices with Impressive Q4 Results and Optimistic FY24 Forecast

Biotechnology Stock Bull Market

Kineta Inc Provides Promising Update on VISTA101 Trial for KVA12123 in Advanced Solid Tumor Patients

Recommended

Blink Charging Stock

Blink Charging’s Critical Earnings Test Approaches

1 month ago
Centrus Energy Stock

A Quiet Leader Emerges in the Nuclear Energy Revival

3 months ago
Costco Stock

Costco’s Bold Membership Strategy: Rewarding Premium Customers

3 months ago
UiPath Registered (A) Stock

UiPath Leadership Under Scrutiny Ahead of Earnings Report

1 month ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin ASML BioNTech Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Prospect Capital Faces Analyst Doubts Amid Strategic Shift

Lennar Shares Face Cautious Outlook Amid Housing Market Uncertainty

Bath & Body Works Stock: Assessing the Post-Candle Day Landscape

IBM’s Strategic Gambit: A Potential $11 Billion Acquisition of Confluent

Analyst Confidence Rises for Royal Gold’s Stock Trajectory

Arrowhead Pharmaceuticals Enters Commercial Era with Landmark Drug Approval

Trending

Pony AI Stock
AI & Quantum Computing

Pony AI Gains Momentum with Strategic Moves and Institutional Backing

by Felix Baarz
December 8, 2025
0

The autonomous driving technology firm Pony AI is entering the week bolstered by a series of strategic...

Ginkgo Bioworks Holdings Registered (A) Stock

Ginkgo Bioworks Shares Surge on Major Government Contract Win

December 8, 2025
AbbVie Stock

Navigating Oncology Rivals: AbbVie’s Strategic Position Under Scrutiny

December 8, 2025
Prospect Capital Stock

Prospect Capital Faces Analyst Doubts Amid Strategic Shift

December 8, 2025
Lennar Stock

Lennar Shares Face Cautious Outlook Amid Housing Market Uncertainty

December 8, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Pony AI Gains Momentum with Strategic Moves and Institutional Backing
  • Ginkgo Bioworks Shares Surge on Major Government Contract Win
  • Navigating Oncology Rivals: AbbVie’s Strategic Position Under Scrutiny

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com